Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$46.61 USD

46.61
1,662,105

-1.08 (-2.26%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $46.51 -0.10 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 11% (224 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SNY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Sanofi falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 9,427 13,419 11,947 15,895 10,558
Receivables 9,550 9,270 9,678 8,557 8,889
Notes Receivable 0 0 0 0 0
Inventories 10,462 9,440 10,311 9,540 8,953
Other Current Assets 3,756 3,721 4,225 4,506 3,643
Total Current Assets 33,194 35,850 36,160 38,499 32,044
Net Property & Equipment 10,996 10,398 11,864 10,698 10,883
Investments & Advances 459 713 296 230 4,022
Other Non-Current Assets 0 90 105 95 364
Deferred Charges 6,956 5,669 5,440 4,811 6,086
Intangibles 79,790 75,366 82,182 71,719 68,422
Deposits & Other Assets 3,686 3,516 3,907 3,406 2,987
Total Assets 136,872 133,514 142,258 130,827 126,264
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7,931 7,178 7,312 6,048 5,951
Current Portion Long-Term Debt 2,213 4,398 3,766 3,161 5,100
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 646 605 366 690 0
Other Current Liabilities 15,097 12,776 13,433 11,823 11,483
Total Current Liabilities 26,185 25,248 25,194 21,987 22,827
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2,010 1,940 1,913 2,022 2,569
Convertible Debt 0 0 0 0 0
Long-Term Debt 15,528 15,653 20,258 22,555 22,547
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 10,778 9,487 11,047 11,067 11,015
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 56,400 54,334 60,588 58,694 60,063
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2,738 2,657 2,990 2,876 2,809
Capital Surplus 339 132 629 414 165
Retained Earnings 73,054 70,311 74,551 68,591 57,994
Other Equity 5,623 6,824 4,612 1,058 5,244
Treasury Stock 1,281 744 1,111 805 10
Total Shareholder's Equity 80,472 79,180 81,671 72,133 66,201
Total Liabilities & Shareholder's Equity 136,872 133,514 142,258 130,827 126,264
Total Common Equity 80,472 79,180 81,671 72,133 66,201
Shares Outstanding 2,529.50 2,521.60 2,521.50 2,504.10 2,504.10
Book Value Per Share 31.81 31.40 32.39 28.81 26.44

Fiscal Year End for Sanofi falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 9,427 0 8,716 0
Receivables NA 9,550 0 9,423 0
Notes Receivable NA 0 0 0 0
Inventories NA 10,462 0 10,871 0
Other Current Assets NA 3,756 0 3,676 0
Total Current Assets NA 33,194 0 32,686 0
Net Property & Equipment NA 10,996 0 10,690 0
Investments & Advances NA 459 0 587 0
Other Non-Current Assets NA 0 0 291 0
Deferred Charges NA 6,956 0 6,521 0
Intangibles NA 79,790 0 80,508 0
Deposits & Other Assets NA 3,686 0 3,524 0
Total Assets NA 136,872 0 136,685 0
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 7,931 0 8,031 0
Current Portion Long-Term Debt NA 2,213 0 5,118 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 646 0 411 0
Other Current Liabilities NA 15,097 0 13,162 0
Total Current Liabilities NA 26,185 0 26,998 0
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2,010 0 2,126 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 15,528 0 15,528 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 10,485 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 56,400 0 57,144 0
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2,738 0 2,753 0
Capital Surplus NA 339 0 153 0
Retained Earnings NA 73,054 0 71,633 0
Other Equity NA 5,623 0 6,046 0
Treasury Stock NA 1,281 0 1,044 0
Total Shareholder's Equity NA 80,472 0 79,541 0
Total Liabilities & Shareholder's Equity NA 136,872 0 136,685 0
Total Common Equity 0 80,472 0 79,541 0
Shares Outstanding 2,529.60 2,529.50 2,529.50 2,524.70 2,521.90
Book Value Per Share 0.00 31.81 0.00 31.51 0.00